Bawazir Waleed M
Medical Laboratory Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Hematology Research Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Diagnostics (Basel). 2022 Aug 11;12(8):1936. doi: 10.3390/diagnostics12081936.
A limited number of studies investigated the association between the ABO blood groups and the incidence of venous thromboembolism in individuals with Factor V Leiden; however, discordant findings were reported. Consequently, this systematic review and meta-analysis aimed to evaluate the existing evidence on the susceptibility of the ABO blood group to venous thromboembolism in individuals with Factor V Leiden. All English-published articles on the Web of Science, Scopus, PubMed, EMBASE, and Google Scholar were comprehensively and systematically searched by the author without a time or region limit. Four studies were included in the qualitative synthesis and meta-analysis after the removal of studies that were not eligible. According to the analyses of the fixed and random effects, the point estimates of the effect size and the 95% confidence interval were 0.416 (95% CI: 0.397−0.435) and 0.392 (95% CI: 0.288−0.507), respectively. In contrast, the homogeneity test (Q value) reveals that blood group data distributions have a heterogenous structure (Q = 432.187; p-value < 0.001). The pooled event rates and the 95% CIs for the A, AB, B, and O-blood groups were 0.518 (95% CI: 0.411−0.622), 0.592 (95% CI: 0.495−0.683), 0.205 (95% CI: 0.041−0.612), and 0.283 (95% CI: 0.247−0.322), respectively. According to the findings, people with Factor V Leiden with blood group AB are more likely to develop venous thromboembolism than those with blood groups A, O, and B. The overall statistical significance of the ABO blood group’s susceptibility to venous thromboembolism in individuals with Factor V Leiden was <0.001 (pooled p-value). In conclusion, the current meta-analysis provides an additional indication that blood group AB individuals with Factor V Leiden are at higher risk of developing venous thromboembolism, and blood type B is connected to a lower risk of developing venous thromboembolism.
少数研究调查了ABO血型与携带凝血因子V莱顿突变个体静脉血栓栓塞发生率之间的关联;然而,研究结果并不一致。因此,本系统评价和荟萃分析旨在评估关于携带凝血因子V莱顿突变个体中ABO血型对静脉血栓栓塞易感性的现有证据。作者对科学网、Scopus、PubMed、EMBASE和谷歌学术上所有英文发表的文章进行了全面系统的检索,没有时间或地域限制。在剔除不符合条件的研究后,四项研究被纳入定性合成和荟萃分析。根据固定效应和随机效应分析,效应大小的点估计值和95%置信区间分别为0.416(95%CI:0.397−0.435)和0.392(95%CI:0.288−0.507)。相比之下,同质性检验(Q值)显示血型数据分布具有异质性结构(Q = 432.187;p值<0.001)。A、AB、B和O血型的合并事件发生率及95%置信区间分别为0.518(95%CI:0.411−0.622)、0.592(95%CI:0.495−0.683)、0.205(95%CI:0.041−0.612)和0.283(95%CI:0.247−0.322)。根据研究结果,携带凝血因子V莱顿突变的AB血型个体比A、O和B血型个体更易发生静脉血栓栓塞。ABO血型对携带凝血因子V莱顿突变个体静脉血栓栓塞易感性的总体统计学意义<0.001(合并p值)。总之,当前的荟萃分析进一步表明,携带凝血因子V莱顿突变的AB血型个体发生静脉血栓栓塞的风险较高,而B血型与发生静脉血栓栓塞的风险较低有关。